Abstract
Routine use of platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) has shown the greatest benefits in patients with high risk for complications and in those with inadequate platelet antagonism. Now, in a partially industry-supported, multicenter, double-blind trial, researchers randomized 2159 low- and intermediate-risk patients (>95% in Europe) to placebo or the GPIIb/IIIa inhibitor abciximab. …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
